People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharma, Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | — | Pharma | Series C | $98.6M | $680.0M | 2010 |
| Eyenovia, Inc. | — | Pharmaceuticals | Series C | $66.0M | $312.3M | 2016 |
| Avid Radiopharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $63.1M | $1.2B | 2009 |
| Kindred Biosciences, Inc. | — | Biotechnology | Series A | $14.8M | $192.0M | 2013 |
| Corinthian Ophthalmic, Inc. | — | Other Health Care | Seed | $12.9M | $40.6M | 2010 |
| Taxis Pharmaceuticals Inc. | — | Pharmaceuticals | Series A | $10.6M | $35.3M | 2016 |
| Tonix Pharmaceuticals Holding Corp. | — | Pharmaceuticals | Series A | $10.3M | $9.7M | 2012 |
| Peninsula Skincare Labs, Inc. | — | Other Health Care | Seed | $3.6M | $7.4M | 2011 |
| Delpor, Inc. | — | Pharmaceuticals | Pre-Seed | $1.4M | $22.2M | 2013 |
Ernest Mario at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ernest Mario on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FRED ESHELMAN | 2 | 5 |
| Charles Mather | 2 | 2 |
| William Harris | 1 | 9 |
| Douglas Crawford | 1 | 8 |
| Anthony Sun | 1 | 8 |
| Curt LaBelle | 1 | 7 |
| Gary J. Kurtzman | 1 | 6 |
| BARRY BUTLER | 1 | 6 |
| Tsontcho Ianchulev | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
| David Moss | 1 | 5 |
| Rajen Dalal | 1 | 5 |
| Andrew Sinclair | 1 | 5 |
| Mike Sullivan | 1 | 4 |
| Richard Chin | 1 | 4 |
| Matthew Pauls | 1 | 4 |
| JOHN MACK | 1 | 3 |
| Samuel Saks | 1 | 3 |
| John Rhodes | 1 | 3 |
| Gregory Sullivan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.